Beam Therapeutics Inc. (BEAM)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
24.43 USD
-0.70
(-2.786%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 24.87 +0.44 (1.801%) ⇧ (Oct. 13, 2026, 4:58 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 9:57 a.m. EDT
The long-term investment case is severely compromised by deteriorating fundamentals. The company is burning through cash with negative free cash flow and operating margins that are effectively infinite losses due to the denominator being zero or negative. Crucially, the five-year price trajectory shows a cumulative decline of over 10%, driven by two consecutive years of double-digit revenue contractions (-46% and -52%). This multi-year decline signals that the market has already priced in a failure to execute or a lack of commercial viability, rendering any 'value' argument moot as the business quality appears to be eroding. While the short-term chart shows some recent recovery and a 'strong buy' analyst consensus based on potential pipeline milestones, the underlying economics are broken. The options market reflects this uncertainty with high implied volatility and a distinct skew toward downside protection, suggesting that even optimistic catalysts may not be enough to reverse the structural trend without a massive, unforeseen breakthrough. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.080266 |
| AutoTheta | 0.081472 |
| AutoETS | 0.081828 |
| AutoARIMA | 0.081828 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.402 |
| Excess Kurtosis | -0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.173 |
| Revenue per Share | 1.511 |
| Market Cap | 2,523,317,760 |
| Forward P/E | -5.15 |
| Beta | 2.20 |
| Profit Margins | -55.45% |
| Website | https://beamtx.com |
As of Oct. 10, 2026, 9:57 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional breakout. Call volume is heavy at strikes 28 and 30 for the October expiration, suggesting a hope for a rally, while massive open interest walls exist at deep out-of-the-money strikes (50) for later expirations, indicating a bet on extreme moves in either direction. However, put volume is notably elevated relative to calls at the November and January expirations, with heavy open interest at strikes 23 and 28, reflecting a strong fear of downside continuation or a failed catalyst event.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.011408329 |
| Address1 | 238 Main Street |
| All Time High | 138.522 |
| All Time Low | 13.0 |
| Ask | 31.01 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,888,070 |
| Average Daily Volume3 Month | 1,875,695 |
| Average Volume | 1,875,695 |
| Average Volume10Days | 1,888,070 |
| Beta | 2.201 |
| Bid | 17.89 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 10.685 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 24.43 |
| Current Ratio | 14.572 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 24.93 |
| Day Low | 24.085 |
| Debt To Equity | 23.173 |
| Display Name | Beam Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,771,938,000 |
| Earnings Call Timestamp Start | 1,771,938,000 |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -355,780,992 |
| Ebitda Margins | -2.2801402 |
| Enterprise To Ebitda | -4.316 |
| Enterprise To Revenue | 9.841 |
| Enterprise Value | 1,535,615,872 |
| Eps Current Year | -4.45352 |
| Eps Forward | -4.74137 |
| Eps Trailing Twelve Months | -0.68 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.5073 |
| Fifty Day Average Change | -2.077299 |
| Fifty Day Average Change Percent | -0.07836706 |
| Fifty Two Week Change Percent | -1.1408329 |
| Fifty Two Week High | 38.26 |
| Fifty Two Week High Change | -13.829998 |
| Fifty Two Week High Change Percent | -0.3614741 |
| Fifty Two Week Low | 20.23 |
| Fifty Two Week Low Change | 4.200001 |
| Fifty Two Week Low Change Percent | 0.2076125 |
| Fifty Two Week Range | 20.23 - 38.26 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,999,400,000 |
| Float Shares | 88,329,323 |
| Forward Eps | -4.74137 |
| Forward P E | -5.152519 |
| Free Cashflow | -241,844,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 540 |
| Fullday Change | -0.25999832 |
| Fullday Change Percent | -1.0346134 |
| Fullday Price | 24.87 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -1.61905 |
| Gross Profits | -252,628,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01204 |
| Held Percent Institutions | 1.07909 |
| Implied Shares Outstanding | 103,287,665 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. |
| Long Name | Beam Therapeutics Inc. |
| Market | us_market |
| Market Cap | 2,523,317,760 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_564610577 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -86,520,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,516,087,519 |
| Number Of Analyst Opinions | 13 |
| Open | 24.84 |
| Operating Cashflow | -359,376,992 |
| Operating Margins | -258.27142 |
| Overall Risk | 7 |
| Phone | 857 327 8775 |
| Post Market Change | 0.44000053 |
| Post Market Change Percent | 1.8010664 |
| Post Market Price | 24.87 |
| Post Market Time | 1,791,925,086 |
| Previous Close | 25.13 |
| Price Eps Current Year | -5.485549 |
| Price Hint | 2 |
| Price To Book | 2.2863827 |
| Price To Sales Trailing12 Months | 16.171484 |
| Profit Margins | -0.55449003 |
| Quick Ratio | 14.254 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.69999886 |
| Regular Market Change Percent | -2.785511 |
| Regular Market Day High | 24.93 |
| Regular Market Day Low | 24.085 |
| Regular Market Day Range | 24.085 - 24.93 |
| Regular Market Open | 24.84 |
| Regular Market Previous Close | 25.13 |
| Regular Market Price | 24.43 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 1,667,903 |
| Return On Assets | -0.17013 |
| Return On Equity | -0.08184 |
| Revenue Growth | -0.942 |
| Revenue Per Share | 1.511 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 103,287,665 |
| Shares Percent Shares Out | 0.2667 |
| Shares Short | 27,548,815 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 25,802,667 |
| Short Name | Beam Therapeutics Inc. |
| Short Percent Of Float | 0.4124 |
| Short Ratio | 14.33 |
| Source Interval | 15 |
| State | MA |
| Symbol | BEAM |
| Target High Price | 80.0 |
| Target Low Price | 26.0 |
| Target Mean Price | 52.15385 |
| Target Median Price | 45.0 |
| Total Cash | 1,152,926,976 |
| Total Cash Per Share | 11.538 |
| Total Debt | 247,358,000 |
| Total Revenue | 156,035,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.68 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 28.427275 |
| Two Hundred Day Average Change | -3.9972744 |
| Two Hundred Day Average Change Percent | -0.14061406 |
| Type Disp | Equity |
| Volume | 1,667,903 |
| Website | https://beamtx.com |
| Zip | 2,142 |